Marimastat is primarily used in research and clinical settings as a matrix metalloproteinase (MMP) inhibitor. Its application focuses on investigating its potential to inhibit tumor growth and metastasis by blocking enzymes that degrade the extracellular matrix, a process crucial for cancer progression. It has been studied in clinical trials for various cancers, including pancreatic, ovarian, and colorectal cancers, to assess its efficacy in slowing disease progression. Additionally, Marimastat has been explored in conditions involving excessive tissue remodeling, such as arthritis and fibrosis, due to its ability to modulate MMP activity. Its role in these areas highlights its significance in therapeutic research targeting enzyme-mediated pathological processes.